Superpower LegitScript and Accreditation Status: Is Superpower Legit?

What Is LegitScript Certification and Why Does It Matter?

LegitScript certification is an independent, third-party accreditation program that verifies online healthcare businesses and pharmacies meet legal and safety standards. Google, Meta, and Microsoft require LegitScript approval before allowing pharmaceutical or telehealth advertisers to run paid campaigns. The absence of certification does not make a company illegal, but it does mean no independent body has formally verified compliance.

LegitScript evaluates applicants against criteria that include valid state pharmacy licensure, prescriber credential verification, patient safety protocols, and compliance with federal drug law. Its standards align closely with the National Association of Boards of Pharmacy (NABP) guidelines and U.S. Federal requirements.

How to Check a Company's Status Yourself

The LegitScript merchant database is publicly accessible. Searching "Superpower" or "getsuperpower.com" returns no certified listing as of July 2025. That single data point should prompt patients to run additional checks before sharing personal health information or payment details.

What LegitScript Certification Actually Verifies

A certified listing confirms that LegitScript has reviewed state licensure documents, inspected prescribing workflows, and confirmed that controlled substances are not dispensed without a valid practitioner-patient relationship. The FDA's own framework for internet pharmacies cross-references many of these same criteria under the Ryan Haight Online Pharmacy Consumer Protection Act of 2008 [1].

Superpower's Business Model: Labs, GLP-1s, and Peptides

Superpower positions itself as a subscription concierge platform. Members pay a monthly or annual fee for access to at-home lab testing, physician review, and prescriptions covering GLP-1 receptor agonists, peptides such as BPC-157 or TB-500, and testosterone replacement therapy.

This model sits at the intersection of three heavily regulated categories: prescription drugs, compounded preparations, and direct-to-consumer lab testing. Each category carries distinct legal exposure.

GLP-1 Prescriptions and Compounding Risk

The FDA placed semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) on its drug shortage list in 2022 and 2023, which temporarily allowed 503A and 503B compounding pharmacies to produce copies. The FDA declared the shortage for semaglutide resolved in February 2025 and for tirzepatide in March 2025 [2]. After those declarations, 503A pharmacies had until May 22, 2025 to wind down compounded semaglutide, and 503B outsourcing facilities had until May 22, 2025 as well, under an FDA enforcement discretion timeline.

Any telehealth platform still prescribing compounded semaglutide or tirzepatide after those deadlines faces direct FDA enforcement risk. Patients who receive compounded GLP-1 products ordered through Superpower or any other platform after the shortage resolution should confirm the dispensing pharmacy's 503A or 503B registration directly on the FDA's database [3].

STEP-1 (N=1,961) showed that FDA-approved semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [4]. That efficacy profile is what drove massive consumer demand and the parallel growth of compounding. The compounding window, however, has now legally closed for most preparations.

Peptides: An Even Grayer Regulatory Zone

Peptides such as BPC-157, TB-500, and CJC-1295 are not FDA-approved drugs. The FDA classifies most research peptides as unapproved drugs subject to enforcement discretion. In 2024, the FDA issued warning letters to multiple compounding pharmacies dispensing BPC-157, citing lack of evidence of safety and effectiveness [5]. Any telehealth service prescribing these compounds is operating in a space the FDA has explicitly flagged as non-compliant with the Federal Food, Drug, and Cosmetic Act.

Superpower Complaints: BBB, Trustpilot, and Patient Reports

BBB Standing

The Better Business Bureau shows no BBB accreditation for Superpower as of July 2025. BBB accreditation requires a company to respond to complaints within a defined window, maintain transparent business practices, and meet BBB's Code of Business Practices. The absence of accreditation does not equal a pattern of fraud, but it removes one accountability layer.

Patient-reported complaints visible on public review platforms cluster around three themes: billing disputes related to subscription auto-renewal, delays in lab result delivery or physician follow-up, and difficulties canceling service. These are operational complaints rather than clinical safety events, but they signal a customer-service model that may not scale smoothly.

What Independent Review Aggregators Show

Review data on Trustpilot and Google Business as of mid-2025 is mixed. Positive reviews frequently highlight the convenience of at-home lab draws and the breadth of biomarker panels. Negative reviews describe a pattern of receiving prescriptions for compounded drugs without a synchronous (live video or phone) clinical encounter, which raises compliance questions under the Ryan Haight Act [1].

The Ryan Haight Act requires at least one in-person medical evaluation before prescribing a controlled substance via the internet. Testosterone is a Schedule III controlled substance. If Superpower or any of its affiliated prescribers are issuing testosterone prescriptions after only an asynchronous questionnaire and lab review, that practice may violate federal law regardless of whether state telemedicine rules appear to permit it.

How to File a Complaint

Patients with concerns about a telehealth prescriber can file complaints with:

• Their state medical board (find the correct board at the Federation of State Medical Boards directory)
• The FDA's MedWatch program for adverse drug events [6]
• The FTC for billing or consumer protection issues
• The NABP for pharmacy-related complaints

State Pharmacy Board Compliance and the 503A/503B Framework

Understanding 503A vs. 503B

A 503A pharmacy compounds medications for individual patients based on a valid prescription. A 503B outsourcing facility compounds in bulk without patient-specific prescriptions and is subject to more rigorous FDA oversight including cGMP inspections. Both must register with the FDA and may not compound drugs that are commercially available in adequate supply [7].

Superpower's partner pharmacies should hold 503A registration if compounding patient-specific formulations. Patients can verify this directly using the FDA's list of registered outsourcing facilities [3] or by asking Superpower's support team for the dispensing pharmacy's DEA and state board license numbers and cross-referencing them independently.

The Importance of PCAB Accreditation

The Pharmacy Compounding Accreditation Board (PCAB), administered through ACHC, accredits compounding pharmacies that voluntarily submit to independent quality audits. PCAB-accredited pharmacies have demonstrated compliance with USP 795, USP 797, and USP 800 standards for non-sterile and sterile preparations. A telehealth platform that routes prescriptions exclusively through PCAB-accredited compounders offers meaningfully stronger quality assurance than one that does not.

There is no public documentation indicating that Superpower restricts its pharmacy network to PCAB-accredited facilities.

A Practical Accreditation Checklist for Evaluating Any Telehealth Platform

Use this framework when reviewing Superpower or any concierge telehealth service prescribing compounded or off-label drugs.

Tier 1: Non-Negotiable Verification Steps

These checks cost nothing and take under 10 minutes:

1. LegitScript search. Go to legitscript.com and search the company domain. A "not certified" or absent result should trigger all remaining checks.
2. FDA outsourcing facility registry. Cross-reference any compounding pharmacy name against the FDA's 503B database [3]. For 503A pharmacies, search the NABP Pharmacy Finder tool.
3. Prescriber license check. Every physician or nurse practitioner signing your prescription must hold an active, unrestricted license in your state. Verify at your state medical board's public license search.
4. DEA registration. For controlled substances (testosterone, any scheduled peptide), the prescribing clinician must hold a valid DEA registration. The DEA does not maintain a public registrant lookup for individuals, but the prescribing clinician can confirm their DEA number and you can request it.

Tier 2: Quality Signals Worth Requesting

Ask Superpower or any similar platform directly:

• Which compounding pharmacy fulfills each drug class (GLP-1, peptides, TRT)?
• Does that pharmacy hold PCAB accreditation?
• Is a synchronous clinical encounter (live video or phone call) available before a controlled-substance prescription is issued?
• What is the process for reporting an adverse drug reaction?

Platforms that cannot answer these questions in writing within 48 hours are signaling a support infrastructure that may not meet the standard expected by the American Telemedicine Association's practice guidelines [8].

Tier 3: Red Flags That Should Stop Enrollment

• Active FDA warning letters against the dispensing pharmacy
• Compounded semaglutide or tirzepatide still offered after May 2025
• No synchronous visit option for Schedule III substances
• Auto-renewal billing with no explicit written cancellation policy disclosed at checkout
• Prescriptions issued before any lab work is reviewed

What Superpower Does Well: A Fair Assessment

Criticism of accreditation gaps should not overshadow genuine value. Several aspects of Superpower's model address real deficiencies in traditional primary care.

Comprehensive Lab Panels

Superpower offers broad biomarker panels that go well beyond standard annual bloodwork. Panels may include testosterone (total and free), SHBG, IGF-1, thyroid function (TSH, free T3, free T4), metabolic markers, and inflammatory markers such as hsCRP. Most primary care visits allocate 15 minutes and may order only a basic metabolic panel. Catching subclinical hypothyroidism or low testosterone at the lab level before symptoms progress has real preventive value.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy states that a diagnosis of hypogonadism requires both "unequivocally low serum testosterone concentrations and clinical symptoms," confirmed on two separate morning measurements [9]. Superpower's lab model supports this two-measurement standard if the platform is designed to require it.

Physician Oversight Infrastructure

Superpower states that board-certified physicians review lab results and approve treatment plans. The presence of a physician in the workflow, rather than only a nurse practitioner operating under a collaborative agreement, is a positive clinical signal. Patients should ask specifically about the specialty and board certification of the reviewing clinician.

FDA Enforcement Trends Relevant to Superpower's Drug Offerings

The FDA has intensified enforcement activity against telehealth platforms and compounding pharmacies since 2023. Key enforcement signals include:

• Warning letters to compounders producing semaglutide after the shortage ended [2]
• A 2024 advisory warning about unlicensed drugs marketed as peptide "research chemicals" [5]
• Increased scrutiny of telehealth platforms routing controlled substance prescriptions without meeting Ryan Haight Act requirements [1]

The FDA's current enforcement position, as summarized in its April 2025 guidance on compounded GLP-1s, states: "Patients should be aware that compounded drugs, including compounded GLP-1 receptor agonist drugs, are not FDA-approved and FDA has not reviewed them for safety, effectiveness, or quality" [2].

That is a direct, named regulatory statement. Patients deserve to read it before enrolling in any platform that includes compounded GLP-1s in its drug menu.

How Superpower Compares to LegitScript-Certified Competitors

Several telehealth platforms in the GLP-1 and TRT space do hold LegitScript certification, including Hims and Hers Health (HIMS, listed on NYSE) and, for its pharmacy operations, various NABP-accredited digital pharmacies. Certification does not guarantee superior clinical outcomes, but it provides an external audit layer that non-certified platforms lack.

A patient choosing between a certified and a non-certified platform for the same drug at comparable pricing should factor the audit layer into the cost-benefit analysis. The marginal monthly cost difference is often under $30. The downside risk of receiving an adulterated or mislabeled compounded product, while statistically uncommon, is not zero. A 2023 analysis of FDA inspection records found that 76% of 503A pharmacies inspected between 2018 and 2022 had at least one observed deviation from quality standards [10].

That figure is not a condemnation of all compounding pharmacies. It is a reminder that quality variance exists and that accreditation reduces, though does not eliminate, that variance.

Practical Steps Before Enrolling with Superpower

Run through this sequence before submitting payment information:

1. Search getsuperpower.com on LegitScript. Note the result.
2. Ask support to name the dispensing pharmacy for each drug class you plan to use.
3. Verify that pharmacy on the FDA 503B registry or your state pharmacy board website.
4. Review the subscription cancellation policy in writing before entering credit card details.
5. Confirm a synchronous visit is available for any controlled-substance prescription.
6. Ask whether compounded semaglutide or tirzepatide is still in the drug formulary. If the answer is yes and the date is after May 22, 2025, request a written explanation of the legal basis.

Superpower may update its accreditation posture, pharmacy partnerships, or compliance infrastructure after this article's publication date of July 14, 2025. The verification steps above remain valid regardless of when you are reading this, because they point to primary regulatory sources that update in real time.